One of the main issues encountered by therapeutic antibodies for the treatment of neurodegenerative disorders such as Alzheimer’s disease (AD) is the difficulty of crossing the blood-brain barrier (BBB) to access the central nervous system. To overcome these problems, several attempts have been made using endothelial transmembrane proteins where antibodies can bind. One of these efforts involves transferrin receptor 1 (TfR1).
Monte Rosa Therapeutics Inc. has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop molecular glue degraders against targets in cancer and neurological diseases previously considered impossible to drug.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified 3-alkynyl carboxamides acting as legumain (asparaginyl endopeptidase; LGMN) inhibitors.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have disclosed zwitterionic compounds reported to be useful for the treatment of bacterial infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented imidazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists. They are reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and ocular disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, neurodegeneration, neuroinflammation, pain and psychiatric disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 (QSK) inhibitors reported to be useful for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neuroinflammation, neurodegeneration, pain, cancer, diarrhea, inflammatory bowel disease, irritable bowel syndrome and psychiatric disorders.
Poseida Therapeutics Inc. has received FDA clearance of its IND application for P-CD19CD20-ALLO1, an allogeneic dual chimeric antigen receptor (CAR) T-cell product candidate being developed for relapsed or refractory B-cell malignancies in partnership with F. Hoffmann-La Roche Ltd. The company is actively focused on opening clinical sites for a phase I study in adults with relapsed or refractory B-cell malignancies.
